Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis

被引：0
|
作者：
Xiaoying Sun
Raheleh Roudi
Ting Dai
Shangya Chen
Bin Fan
Hongjin Li
Yaqiong Zhou
Min Zhou
Bo Zhu
Chengqian Yin
Bin Li
Xin Li
机构：
[1] Shanghai University of Traditional Chinese Medicine,Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine
[2] Shanghai Academy of Traditional Chinese Medicine,Institute of Dermatology
[3] Iran University of Medical Sciences,Oncopathology Research Center
[4] Shandong Academy of Occupational Health and Occupational Medicine,Department of Toxicology
[5] Shandong Academy of Medical Science,Department of Pharmacology & Experimental Therapeutics
[6] Boston University School of Medicine,Department of Dermatology
[7] Shaanxi Traditional Chinese Medicine Hospital,undefined
来源：
BMC Cancer | / 19卷
关键词：
Non-small cell lung cancer; Oncology; Programmed cell death protein-1; Programmed cell death ligand 1; Inhibitor; Immune-related adverse event; Meta-analysis; Systematic review;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis
    Sun, Xiaoying
    Roudi, Raheleh
    Dai, Ting
    Chen, Shangya
    Fan, Bin
    Li, Hongjin
    Zhou, Yaqiong
    Zhou, Min
    Zhu, Bo
    Yin, Chengqian
    Li, Bin
    Li, Xin
    BMC CANCER, 2019, 19 (1)
  • [2] Immune-related adverse events as a predictor marker of response to programmed cell death 1/programmed death-ligand 1 axis inhibitors in patients with non-small cell lung cancer
    Charpidou, Andriani
    Patriarcheas, Vasilios
    Vathiotis, Ioannis
    Kokotou, Eleni
    Syrigos, Nikos
    Mani, Maria
    Stournara, Lamprini
    Gkiozos, Ioannis
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [3] Adverse cardiac events in the treatment of non-small cell lung cancer with programmed death-1and programmed death-ligand 1 inhibitors A protocol for systematic review and meta-analysis
    Li, Honglin
    Han, Deting
    Feng, Xiaoteng
    Yu, Wenjun
    Xu, Tongtong
    Ma, Tao
    Song, Lucheng
    MEDICINE, 2020, 99 (32) : E21613
  • [4] Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer
    O'Kane, Grainne M.
    Labbe, Catherine
    Doherty, Mark K.
    Young, Kelvin
    Albaba, Hamzeh
    Leighl, Natasha B.
    ONCOLOGIST, 2017, 22 (01): : 70 - 80
  • [5] Immune-related and Common Adverse Events With Programmed Cell Death 1/Programmed Cell Death Ligand 1 inhibitors combined with other Anticancer Therapy for Solid Tumors: A Systematic Review and Meta-analysis
    Inoue, T.
    Narukawa, M.
    CLINICAL ONCOLOGY, 2025, 37
  • [6] Fatal Adverse Events Associated With Programmed Cell Death Ligand 1 Inhibitors: A Systematic Review and Meta-Analysis
    Wang, Xuewen
    Wu, Shijie
    Chen, Yaying
    Shao, Erqian
    Zhuang, Tingting
    Lu, Linbin
    Chen, Xiong
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [7] Safety and efficacy of combination therapy using programmed cell death protein-1/programmed cell death ligand-1 inhibitors and radiotherapy in patients with non-small-cell lung cancer: A systematic review and meta-analysis
    Geng, Yichao
    Zhang, Qiuning
    Feng, Shuangwu
    Li, Chengcheng
    Wang, Lina
    Zhao, Xueshan
    Yang, Zhen
    Li, Zheng
    Luo, Hongtao
    Liu, Ruifeng
    Lu, Bing
    Wang, Xiaohu
    CANCER MEDICINE, 2021, 10 (04): : 1222 - 1239
  • [8] Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer A Systematic Review and Meta-analysis
    Duan, Jianchun
    Cui, Longgang
    Zhao, Xiaochen
    Bai, Hua
    Cai, Shangli
    Wang, Guoqiang
    Zhao, Zhengyi
    Zhao, Jing
    Chen, Shiqing
    Song, Jia
    Qi, Chuang
    Wang, Qing
    Huang, Mengli
    Zhang, Yuzi
    Huang, Depei
    Bai, Yuezong
    Sun, Feng
    Lee, J. Jack
    Wang, Zhijie
    Wang, Jie
    JAMA ONCOLOGY, 2020, 6 (03) : 375 - 384
  • [9] Fatal adverse events associated with programmed cell death protein 1 or programmed cell death-ligand 1 monotherapy in cancer
    Zhao, Bin
    Zhao, Hong
    Zhao, Jiaxin
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [10] Prognostic Role of Soluble Programmed Death Ligand 1 in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
    Liao, Guixiang
    Zhao, Zhihong
    Qian, Yuting
    Ling, Xiean
    Chen, Shanyi
    Li, Xianming
    Kong, Feng-Ming
    FRONTIERS IN ONCOLOGY, 2021, 11
12345